SCHEMBL3099202

SCHEMBL3099202

CCc1oc(-c2ccc(OC)cc2)cc1C=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.51
BCHE P06276 1/20 0.47
ALOX5 P09917 1/20 0.47
ALOX15 P16050 1/20 0.47
ACHE P22303 1/20 0.47
MAOB P27338 5/20 0.44
ALDH1A1 P00352 5/20 0.43
CYP3A4 P08684 4/20 0.43
KDM4E B2RXH2 3/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 3/20 0.43
NPC1 O15118 2/20 0.43
LMNA P02545 2/20 0.43
THRB P10828 2/20 0.43
RAB9A P51151 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ERN1 O75460 2/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3905767 0.85 ALDH1A1 (0.48) MAOBALDH1A1CYP3A4KDM4EMAPT
SCHEMBL3106747 0.81 EGFR (0.57) EGFRBCHEALOX5ALOX15ACHE
SCHEMBL3104730 0.81 ALDH1A1 (0.43) EGFRMAOBALDH1A1CYP3A4KDM4E
SCHEMBL3110166 0.75 EGFR (0.49) EGFRMAOBALDH1A1CYP3A4KDM4E
SCHEMBL3106777 0.74 ALDH1A1 (0.52) EGFRMAOBALDH1A1KDM4EMAPT
SCHEMBL18922767 0.73 ABCB1 (0.69) MAOBALDH1A1CYP3A4KDM4EMAPT
SCHEMBL3927669 0.72 ESR1 (0.56) EGFRBCHEALOX5ALOX15ACHE
SCHEMBL3090890 0.72 ALDH1A1 (0.43) BCHEALOX5ALOX15ACHEMAOB
SCHEMBL13790859 0.72 EGFR (0.57) EGFRMAOBALDH1A1CYP3A4KDM4E
SCHEMBL3105318 0.72 ALDH1A1 (0.40) EGFRALDH1A1CYP3A4KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR EGFR 2791/4885BCHE 1252/4885ALOX5 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.